阅读说明：本技术 一种基于肠道菌改善肌肉萎缩食品配方 (Food formula for improving muscular atrophy based on intestinal bacteria ) 是由 刘西爱 于 2021-07-31 设计创作，主要内容包括：本发明涉及一种基于肠道菌改善肌肉萎缩食品配方,包括以下重量百分比原料：亮氨酸3-8％、异亮氨酸3-8％、菊粉12-15％、乳清蛋白40-50％、大豆分离蛋白20-30％、低聚果糖0.5-2％、铁0.1-0.3％、锌0.1-0.3％、精氨酸0.5-2％、甘氨酸0.5-2％,蛋氨酸0.5-2％、辣木叶粉1-3％。本发明的优点：本发明产品口味适合大多数人群,能够有效改善肌肉状态,能够塑造健康的肠道微环境。(The invention relates to a food formula for improving muscular atrophy based on intestinal bacteria, which comprises the following raw materials in percentage by weight: 3-8% of leucine, 3-8% of isoleucine, 12-15% of inulin, 40-50% of whey protein, 20-30% of soybean protein isolate, 0.5-2% of fructo-oligosaccharide, 0.1-0.3% of iron, 0.1-0.3% of zinc, 0.5-2% of arginine, 0.5-2% of glycine, 0.5-2% of methionine and 1-3% of moringa leaf powder. The invention has the advantages that: the product of the invention has a taste suitable for most people, can effectively improve the muscle state, and can shape a healthy intestinal microenvironment.)

1. A food formula for improving muscle atrophy based on intestinal bacteria is characterized in that: comprises the following raw materials in percentage by weight: 3-8% of leucine, 3-8% of isoleucine, 12-15% of inulin, 40-50% of whey protein, 20-30% of soybean protein isolate, 0.5-2% of fructo-oligosaccharide, 0.1-0.3% of iron, 0.1-0.3% of zinc, 0.5-2% of arginine, 0.5-2% of glycine and 0.5-2% of methionine. And moringa oleifera leaf powder 1-3%.

2. The enterobacteria-based food formulation for ameliorating muscle atrophy of claim 1, wherein the enterobacteria-based food formulation comprises: the material comprises the following raw materials in percentage by weight: leucine 5%, isoleucine 5%, inulin 13.7%, whey protein 45%, soybean protein isolate 25%, fructo-oligosaccharide 1%, iron 0.2%, zinc 0.1%, arginine 1%, glycine 1%, methionine 1%, and moringa leaf powder 2%.

Technical Field

The invention relates to the technical field of health-care food, in particular to a food formula for improving muscular atrophy based on intestinal bacteria.

Background

Skeletal muscle is the largest "reservoir" of protein in the human body, providing protein to the body in the event of stress or external injury. When the body's demand for protein and energy increases and the corresponding intake of external nutrients decreases, muscle degradation rates are greater than synthesis rates, resulting in muscle loss. In many disease states, muscle loss is easily induced in patients. Clinical observation shows that patients with leukemia all have skeletal muscle atrophy with different degrees, and a large amount of protein is lost in the body. Worldwide, at least 1% of the population receives GC treatment for a long time each year. Glucocorticoid also causes muscular atrophy, and the white paper published in 2018, 6 months, the epidemic situation and prevention and treatment strategy of Chinese chronic respiratory diseases shows that' 4570 ten thousand adult asthma patients exist in China, wherein 2579 ten thousand are male and 2000 ten thousand are female. The 'red cross' statistical result in 2017 shows that nearly million patients wait for hematopoietic stem cell transplantation patients in China at present. As many GC users are generally exposed to muscle atrophy and loss, which is common and often overlooked in the clinic, long-term muscle atrophy directly leads to decreased survival fitness of patients and even increased mortality of related diseases. Therefore, a new technology for improving the muscular atrophy is provided, and the survival fitness of the patient is improved.

Disclosure of Invention

The technical problem to be solved by the invention is to solve the problems and provide a food formula for improving muscle atrophy based on intestinal bacteria.

In order to solve the technical problems, the technical scheme provided by the invention is as follows: a food formula for improving muscle atrophy based on intestinal bacteria comprises the following raw materials in percentage by weight: 3-8% of leucine, 3-8% of isoleucine, 12-15% of inulin, 40-50% of whey protein, 20-30% of soybean protein isolate, 0.5-2% of fructo-oligosaccharide, 0.1-0.3% of iron, 0.1-0.3% of zinc, 0.5-2% of arginine, 0.5-2% of glycine, 0.5-2% of methionine and 1-3% of moringa leaf powder.

Further, the paint comprises the following raw materials in percentage by weight: leucine 5%, isoleucine 5%, inulin 13.7%, whey protein 45%, soybean protein isolate 25%, fructo-oligosaccharide 1%, iron 0.2%, zinc 0.1%, arginine 1%, glycine 1%, methionine 1%, and moringa leaf powder 2%.

After adopting the structure, the invention has the following advantages: nutrients necessary for muscle synthesis; change the microenvironment of the intestinal tract; the abundance of core strains for muscle synthesis is improved by using the combination of the contained prebiotics and energy components thereof, and the intestinal bacteria microorganism capable of regulating and controlling muscle synthesis is also provided. The product of the invention has a taste suitable for most people, can effectively improve the muscle state, and can shape a healthy intestinal microenvironment.

Drawings

FIG. 1 is a schematic diagram of a comparative structure of muscles before and after taking of a food formula for improving muscle atrophy based on intestinal bacteria.

Fig. 2 is a structural diagram showing the comparison of relative abundance before and after taking of a food formula for improving muscle atrophy based on intestinal bacteria.

Detailed Description

The present invention will be described in further detail with reference to the accompanying drawings.

With reference to the attached figures 1 and 2,

implementation scheme one

A food formula for improving muscle atrophy based on intestinal bacteria comprises the following raw materials in percentage by weight: 3% of leucine, 3% of isoleucine, 12% of inulin, 40% of whey protein, 20% of soybean protein isolate, 0.5% of fructo-oligosaccharide, 0.1% of iron, 0.1% of zinc, 0.5% of arginine, 0.5% of glycine, 0.5% of methionine and 1% of moringa oleifera leaf powder.

The product of the invention prepares the corresponding components of the formula according to the energy of the core bacteria and the requirements of nutrients. The composition can effectively regulate intestinal microenvironment. Significant muscle improvement was seen with 1-2 months of continuous administration.

Example II

A food formula for improving muscle atrophy based on intestinal bacteria comprises the following raw materials in percentage by weight: leucine 8%, isoleucine 8%, inulin 15%, whey protein 50%, soy protein isolate 30%, fructo-oligosaccharide 2%, iron 0.3%, zinc 0.3%, arginine 2%, glycine 2%, methionine 2%, and moringa leaf powder 3%.

The product of the invention prepares the corresponding components of the formula according to the energy of the core bacteria and the requirements of nutrients. The composition can effectively regulate intestinal microenvironment. Significant muscle improvement was seen with 1-2 months of continuous administration.

Example III

A food formula for improving muscle atrophy based on intestinal bacteria comprises the following raw materials in percentage by weight: leucine 5%, isoleucine 5%, inulin 13.7%, whey protein 45%, soybean protein isolate 25%, fructo-oligosaccharide 1%, iron 0.2%, zinc 0.1%, arginine 1%, glycine 1%, methionine 1%, and moringa leaf powder 2%.

The product of the invention prepares the corresponding components of the formula according to the energy of the core bacteria and the requirements of nutrients. The composition can effectively regulate intestinal microenvironment. Significant muscle improvement was seen with 1-2 months of continuous administration.

In summary, the present invention provides essential nutrients for muscle synthesis; change the microenvironment of the intestinal tract; the abundance of core strains for muscle synthesis is improved by using the combination of the contained prebiotics and energy components thereof, and the intestinal bacteria microorganism capable of regulating and controlling muscle synthesis is also provided. The product of the invention has a taste suitable for most people, can effectively improve the muscle state, and can shape a healthy intestinal microenvironment.

The working principle of the invention is as follows: the intestinal flora is an important target spot and is involved in regulating muscle atrophy. First, germ-free mice are able to promote muscle fatty acid metabolism by up-regulating both the AMPK-CPT-1 and Fiaf-PGC-1 α signaling pathways. Secondly, the levels of MuRF1 and Atrogin-1 in gastrocnemius and tibialis can be effectively reduced by supplementing lactobacillus in vitro; at the same time, LC3 and Cathepsin L in the autophagy and lysosomal pathways (the major pathways for skeletal muscle protein degradation) also decreased to varying degrees. In turn, the branched chain essential amino acids (BCAAs), represented by leucine, play a key role in regulating muscle metabolism. The intestinal flora affects the bioavailability of amino acids in the body, and lysine produced by microorganisms can fully meet the requirement of rats and pigs on lysine. In addition, exogenous supplementation with Lactobacillus paracasei NCC2462 directly affected the pattern of amino acid composition in mouse feces. Finally, the improvement of the composition structure of the intestinal microorganisms by the prebiotics can improve the muscle atrophy by improving the composition pattern of the intestinal bacteria.

The present invention and its embodiments have been described above, but the description is not limitative, and the actual structure is not limited thereto. It should be understood that those skilled in the art should understand that they can easily make various changes, substitutions and alterations herein without departing from the spirit and scope of the invention as defined by the appended claims.